Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SEA-CD70 in relapsed or refractory myeloid malignancies
NL-OMON54392Phase 1Recruiting
- Sponsor
- Seagen Inc.
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of SEA-CD70 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Seagen Inc. Primary endpoints: Safety and tolerability, Maximum tolerated dose or recommended expansion dose and 13 more. Started Jan 2022; status: recruiting.
02
Drugs
SEA-CD70
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON54392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54392.